The trading in Xintela AB’s shares commenced last week on Nasdaq First North in Stockholm and the healthcare company is the 11th company to be admitted to trading on Nasdaq’s Nordic markets in 2016.
Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with a particular focus on cartilage damage and brain tumours. The company develops cell therapy products based on an innovative, patented technology, and the key to the company’s operations is the patented marker technology XINMARK. Xintela was founded in 2009, while its research and development operations were initiated in 2013.
“There is a large, unmet need for new and better treatments within cartilage repair and brain tumours, and we are convinced that our technology has great potential in these fields,” said Evy Lundgren-Åkerlund, CEO and founder of Xintela. “The listing at Nasdaq First North is a milestone for Xintela and we hope that the listing will attract more interest in our business.”
